Table 1

Clinical data of the whole cohort as well as clinical and molecular-genetic subtypes
Age [years] Disease duration [years] SPRS [scoring points] Phenotype
HSP-a (n=28) 48.1 (8–75) 19.1 (440) 20.8 (330) complex & pure, see subgroups
HSP-p (n=22) 49.5 (8–75) 21.8 (5–43) 21.5 (3–31) spastic paraparesis, pure phenotype
HSP-c (n=6) 42.8 (22–60) 9.5 (4–18) 18 (8–31) most frequent complicating symptoms: gaze-evoked-nystagmus or ataxia
SPG4 (n=13) 46.1 (8–74) 21.5 (7–37) 20.8 (3–30) spastic paraparesis, pure phenotype
SPG5 (n=1) 48 43 23 pure phenotype
SPG7 (n=3) 38.3 (28–48) 9.7 (4–14) 17.7 (8–31) one pure, two complex phenotypes (see text)

Data are given as mean values and range in brackets for all HSP-patients (HSP-a) and for clinically pure phenotypes (HSP-p), complex phenotypes (HSP-c) as well as molecular-genetic (SPG4, SPG5, SPG7) subgroups.

Wiethoff et al.

Wiethoff et al. BMC Neurology 2012 12:143   doi:10.1186/1471-2377-12-143

Open Data